Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.

Cancer cell - 9 Sept 2024

Eide Christopher A, Brewer Diana, Xie Tao, Schultz Anna Reister, Savage Samantha L, Muratcioglu Serena, Merz Noah, Press Richard D, O'Hare Thomas, Jacob Thomas, Vu Tania Q, Tognon Cristina E, Macey Tara A, Kuriyan John, Kalodimos Charalampos G, Druker Brian J

Abstract excerpt

BCR-ABL1 compound mutations can lead to resistance to ABL1 inhibitors in chronic myeloid leukemia (CML), which could be targeted by combining the ATP-site inhibitor ponatinib and the allosteric inhibitor asciminib. Here, we report the clinical validation of this approach in a CML patient, providing a basis for combination therapy to overcome such resistance.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imidazoles

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Niacinamide

Share to Pyrazoles

Share to Pyridazines

Source

Identifiers

PMID: 39214096
DOI: 10.1016/j.ccell.2024.08.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.PMID 39214096Read ↗

BCR-ABL1 compound mutations drive ponatinib resistance.Semantic proximity Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

A novel hyperactive <i>BCR::ABL1</i> <sup> <i>e6a3</i> </sup> variant confers resistance to combined asciminib plus ponatinib therapySemantic proximity Read ↗

Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutationsSemantic proximity Read ↗

Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.Semantic proximity Read ↗

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.Semantic proximity Read ↗

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Semantic proximity Read ↗

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.Semantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

BCR-ABL1 mutation ≠ ponatinib resistance.Semantic proximity Read ↗

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.Semantic proximity Read ↗

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.